Sidea Semiconductor Equipment
301629
Jiangyin Electrical Alloy
300697
Nanjing Wondux Environmental Protection Technology Corp., Ltd.
688178
4
Zhang Xiaoquan Inc.
301055
5
CGCABLE
834639
US Stock MarketDetailed Quotes
INCY Incyte
- 61.920
- +1.340+2.21%
Close Mar 21 16:00 ET
- 61.920
- 0.0000.00%
Post 19:49 ET
11.98BMarket Cap412.80P/E (TTM)
62.330High60.250Low4.33MVolume60.440Open60.580Pre Close268.47MTurnover2.69%Turnover Ratio412.80P/E (Static)193.52MShares83.95052wk High3.48P/B9.99BFloat Cap50.35052wk Low--Dividend TTM161.34MShs Float153.150Historical High--Div YieldTTM3.43%Amplitude1.850Historical Low61.968Avg Price1Lot Size
Incyte Stock Forum
Sign in to post a comment
Columns Wall Street Today: DJIA, S&P 500 and Nasdaq Composite All End in the Green on St. Patrick's Day
The Dow Jones Industrial Average, S&P 500 and Nasdaq Composite all ended in the green Monday for St. Patrick's Day, rising for a second straight session as markets continued to partially rebound from their recent tariff-induced sell-off.
The $Dow Jones Industrial Average (.DJI.US)$ led the way higher, gaining 353.45 points (0.9%) to end the day at 41.841.63. The $S&P 500 Index (.SPX.US)$ likewise added 3...
The $Dow Jones Industrial Average (.DJI.US)$ led the way higher, gaining 353.45 points (0.9%) to end the day at 41.841.63. The $S&P 500 Index (.SPX.US)$ likewise added 3...
26
1
5
$Incyte (INCY.US)$
Breakthrough: Dual Phase 3 Trials Prove Povorcitinib's Success in Treating Hidradenitis Suppurativa
Breakthrough: Dual Phase 3 Trials Prove Povorcitinib's Success in Treating Hidradenitis Suppurativa
$Incyte (INCY.US)$
Can Incyte's Opzelura Break Through in Prurigo Nodularis? Phase 3 Data Reveals Critical Insights
Can Incyte's Opzelura Break Through in Prurigo Nodularis? Phase 3 Data Reveals Critical Insights
$Incyte (INCY.US)$
Can Incyte's New Clinical Data Revolutionize Prurigo Nodularis Treatment? AAD 2025 Reveals Answers
Can Incyte's New Clinical Data Revolutionize Prurigo Nodularis Treatment? AAD 2025 Reveals Answers
$Incyte (INCY.US)$
AI Meets Drug Discovery: Inside Incyte's $620M Genesis Deal - Will This Transform Pharma R&D?
AI Meets Drug Discovery: Inside Incyte's $620M Genesis Deal - Will This Transform Pharma R&D?
$Incyte (INCY.US)$ $Agenus (AGEN.US)$ Reuters· 2 mins ago
Agenus Inc - Incyte to Terminate Agreement With Agenus Effective February 2026
Agenus Inc - Incyte to Terminate Agreement With Agenus Effective February 2026
$Merck & Co (MRK.US)$ $Incyte (INCY.US)$ is a great company. Buying it would be a good decision, unless Merck massively overpays.
3
Click Here: TYNKR LAB™
U.S. stock markets closed with mixed results, reflecting cautious investor sentiment as major tech earnings approached alongside key economic data. $Dow Jones Industrial Average (.DJI.US)$ fell by 0.36%, while $S&P 500 Index (.SPX.US)$ and $Nasdaq Composite Index (.IXIC.US)$ posted gains of 0.16% and 0.81%, respectively. This divergence highlights sector-specific movements and investor positioning ahead ...
U.S. stock markets closed with mixed results, reflecting cautious investor sentiment as major tech earnings approached alongside key economic data. $Dow Jones Industrial Average (.DJI.US)$ fell by 0.36%, while $S&P 500 Index (.SPX.US)$ and $Nasdaq Composite Index (.IXIC.US)$ posted gains of 0.16% and 0.81%, respectively. This divergence highlights sector-specific movements and investor positioning ahead ...
+2
2
2
🚨 This Week’s PDUFAs:
$Regeneron Pharmaceuticals (REGN.US)$ : 🤔
⇨ Linvoseltamab
‣ Multiple myeloma
‣ PDUFA: 8/22/24 (BLA)
🗓️ Last Week’s PDUFAs:
$Gilead Sciences (GILD.US)$ : Approved 8/14 🎉
⇨ Livdelzi (Seladelpar)
‣ Primary biliary cholangitis (PBC)
‣ PDUFA: 8/14/24 (NDA)
$Ascendis Pharma A/S (ASND.US)$ : Approved 8/12 🎉
⇨ YORVIPATH (palopegteriparatide)
‣ Hypoparathyroidism
‣ PDUFA: 8/14/24 (NDA)
$Syndax Pharmaceuticals (SNDX.US)$ & $Incyte (INCY.US)$ : Approved 8/14 🎉
⇨ Nikt...
$Regeneron Pharmaceuticals (REGN.US)$ : 🤔
⇨ Linvoseltamab
‣ Multiple myeloma
‣ PDUFA: 8/22/24 (BLA)
🗓️ Last Week’s PDUFAs:
$Gilead Sciences (GILD.US)$ : Approved 8/14 🎉
⇨ Livdelzi (Seladelpar)
‣ Primary biliary cholangitis (PBC)
‣ PDUFA: 8/14/24 (NDA)
$Ascendis Pharma A/S (ASND.US)$ : Approved 8/12 🎉
⇨ YORVIPATH (palopegteriparatide)
‣ Hypoparathyroidism
‣ PDUFA: 8/14/24 (NDA)
$Syndax Pharmaceuticals (SNDX.US)$ & $Incyte (INCY.US)$ : Approved 8/14 🎉
⇨ Nikt...
8
No comment yet
Market Insights
Discussing
Chinese stock earnings surge: Will profit sustain the rally?
1. Which sectors are likely to be market highlights this season? 2. With the government's emphasis on technological innovation and sustaina
Moomoo News Global
Mar 4 23:26
China's Two Sessions: Key Takeaways on Stock Price Movements Before and After the Meetings
Chak : louda tarriff , mad har chod powell cut down the interesr rate